Table 2.

Clinical data of the TACIhi and TACIlo patients

Definition of TACIlo and TACIhi subgroups, % of all patients
50/50
40/40
25/25
15/15
Categories
TACIhi
TACIlo
TACIhi
TACIlo
TACIhi
TACIlo
TACIhi
TACIlo
Age of at least 65 y   30   24   28   28   20   40   20   40  
Kappa light chain   65   70   64   80   60   66   50   70  
Lambda light chain   35   26  36 16 40 16 50 20 
Nonsecreting   0   4   0   4  0 18 0 10 
IgA subtype   25   31   24   24   33   27   20   30  
β2-microglobulin at least 4 mg/L   44   37   40   40   40   60   30   60  
C-reactive protein at least 4 mg/L   44   53   40   56   47   67   50   70  
Lactate dehydrogenase at least 190 IU/L   28   16   28   20   27   20   40   30  
Albumin less than 35 g/L   37   37   40   36   47   33   60   40  
Hemoglobin less than 10 g/dL   28   35   36   44  20 47 20 60 
Bone lesions         
   0 lesions   42   20  45 10 43 8 44 0 
   At least 1 lesion   58   80  55 90 57 92 56 100 
Cytogenetic abnormalities         
   Chromosome 13 deletion   22   31   24   32   27   33   30   40  
   t(4;14) translocation  22 6 20 8 27 6 30 0 
   t(11;14) translocation   9   9   12   12   20   6   20   10  
Staging         
   I   9   3   8   3   6   0   4   0  
   II   5   5   5   4   2   3   1   2  
   III   18   24   12   18   7   12   5   8  
   P*
 		 .1
 
 		 .02
 
 		 .02
 
 		 .08
 
 
Definition of TACIlo and TACIhi subgroups, % of all patients
50/50
40/40
25/25
15/15
Categories
TACIhi
TACIlo
TACIhi
TACIlo
TACIhi
TACIlo
TACIhi
TACIlo
Age of at least 65 y   30   24   28   28   20   40   20   40  
Kappa light chain   65   70   64   80   60   66   50   70  
Lambda light chain   35   26  36 16 40 16 50 20 
Nonsecreting   0   4   0   4  0 18 0 10 
IgA subtype   25   31   24   24   33   27   20   30  
β2-microglobulin at least 4 mg/L   44   37   40   40   40   60   30   60  
C-reactive protein at least 4 mg/L   44   53   40   56   47   67   50   70  
Lactate dehydrogenase at least 190 IU/L   28   16   28   20   27   20   40   30  
Albumin less than 35 g/L   37   37   40   36   47   33   60   40  
Hemoglobin less than 10 g/dL   28   35   36   44  20 47 20 60 
Bone lesions         
   0 lesions   42   20  45 10 43 8 44 0 
   At least 1 lesion   58   80  55 90 57 92 56 100 
Cytogenetic abnormalities         
   Chromosome 13 deletion   22   31   24   32   27   33   30   40  
   t(4;14) translocation  22 6 20 8 27 6 30 0 
   t(11;14) translocation   9   9   12   12   20   6   20   10  
Staging         
   I   9   3   8   3   6   0   4   0  
   II   5   5   5   4   2   3   1   2  
   III   18   24   12   18   7   12   5   8  
   P*
 		 .1
 
 		 .02
 
 		 .02
 
 		 .08
 
 

We separated 65 newly diagnosed patients with MM into 2 subgroups according to TACI gene expression in MMCs assayed with Affymetrix microarrays. The 2 subgroups represent either 50% (n = 32), 40% (n = 25), 25% (n = 15), or 15% (n = 10) of the patients with highest (TACIhi) or lowest (TACIlo) TACI expression. Data are the percentages of patients within each subgroup with the indicated clinical or biologic parameters. When the percentages were different with the chi-square test (P = .05), the data are shown in italics.

*

P value compares high and low subgroups in each category

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal